In a continued show of financial robustness, Johnson & Johnson (NYSE:JNJ) has declared a 4.2% increase in its quarterly dividend, raising it from $1.19 per share to $1.24 per share. This adjustment marks the 62nd consecutive year the healthcare giant has increased its dividend, underscoring a long-standing commitment to delivering shareholder value. The new dividend rate elevates the annual payout to $4.96 per share, up from the previous $4.76 per share. Johnson & Johnson has scheduled the next quarterly dividend payout for June 4, 2024, with May 21, 2024, set as the record date for shareholders eligible to receive the dividend. Additionally, the ex-dividend date is announced as May 20, 2024.

Johnson & Johnson (NYSE:JNJ) reported lower-than-expected quarterly revenue as sales from its leading psoriasis treatment, Stelara, underperformed amidst looming market competition. The pharmaceutical giant saw its shares drop nearly 2% in premarket trading due to flat sales of Stelara, which amounted to $2.45 billion for the first quarter, falling short of the projected $2.6 billion. Despite the setback with Stelara, whose key patent expired last year, J&J has managed to delay the entry of biosimilar competitors in the U.S. until 2025. This strategic move is expected to bolster the drug’s contributions to J&J’s revenue through 2024 and 2025. On a brighter note, J&J’s blood cancer therapy Darzalex performed well, with sales increasing by 19% to $2.69 billion, aligning close

Morgan Stanley (NYSE:MS) has announced its financial outcomes for the first quarter of 2024, demonstrating robust growth with net revenues reaching $15.1 billion, up from $14.5 billion in the corresponding quarter last year. The firm's profitability also saw an uplift, with net income hitting $3.4 billion, or $2.02 per diluted share, an increase from the previous year's $3 billion, or $1.70 per diluted share. CEO Ted Pick praised the firm's performance, stating, "In the first quarter of 2024, Morgan Stanley generated net revenues of $15 billion and earnings of $2.02 per share for a 20% return on tangible equity." He highlighted the firm's achievement of $7 trillion in client assets across Wealth and Investment Management, backed by strong net new asset growth, as well as noting the strengt

AT&T (NYSE:T) has released its financial results for the first quarter of 2024, maintaining a steady performance with revenues holding at $30 billion, mirroring figures from the previous year. The Dallas-based telecommunications leader announced a diluted earnings per share (EPS) of $0.47, with an adjusted EPS of $0.55. The company also reported an operating income of $5.8 billion, an adjusted figure of $6 billion, and a net income of $3.8 billion. Additionally, the adjusted EBITDA stood at $11 billion. A notable financial highlight was the significant increase in cash from operating activities, which climbed by $0.9 billion to $7.5 billion. Free cash flow also saw a substantial rise, surging by $2.1 billion to reach $3.1 billion. AT&T's CEO, John Stankey, commented on the quarterl

Zoono Group and its exclusive agent, OSY Group, secured their first major contract with a supermarket chain, marking a pivotal step in Zoono's expansion into the global food supply chain, excluding China and India. The partnership aims to apply Zoono's shelf-life extension technology to reduce food waste. The agreement targets a minimum UK sales benchmark of NZ$2.6 million ($2.4 million) in the first year, leveraging two years of trial results with a UK supermarket chain and a fruit supplier. Both companies plan to share trial results globally, demonstrating Zoono's commitment to providing innovative, eco-friendly antimicrobial solutions. Claim Now

Constellation Brands (NYSE:STZ) experienced a rise in its share value on Thursday following the release of its fourth-quarter earnings, which exceeded analyst forecasts. The company announced a revenue of $2.14 billion, topping predictions of $2.1 billion. Additionally, Constellation Brands reported adjusted earnings of $2.26 per share, outpacing the anticipated $2.10 per share. The company's beer division was highlighted as a key driver of this quarter's success, posting an impressive 11% increase in sales compared to the same period last year. In contrast, the wine and spirits segment didn't perform as well, showing a 6% drop in sales. Despite this dip, the robust performance of the beer business helped bolster the overall quarterly results for Constellation Brands.

Establishment Labs Holdings (NASDAQ:ESTA) has announced a pivotal development in its quest for U.S. market approval of its Motiva Implants. According to a recent filing with the Securities and Exchange Commission (SEC), the U.S. Food and Drug Administration (FDA) has slated a pre-approval inspection of the company's manufacturing facilities for the second quarter of 2024. This scheduled inspection marks a crucial milestone in Establishment Labs' regulatory journey, potentially paving the way for the approval of Motiva Implants in the United States. Read More #UnitedStates #News #Nasdaq #Food #SEC

Full story: https://grafa.com/news/lilium--nasdaq-lilm--triumphs-with-nasdaq-compliance-victory-222941 Lilium (NASDAQ:LILM) has successfully regained compliance with Nasdaq's minimum bid price requirement, as per a recent SEC filing. The company received a notice from Nasdaq Stock Market on May 15, 2024, confirming that it had met the necessary condition of maintaining a closing bid price of at least $1 per share for a minimum of 10 consecutive trading days. This development comes after Lilium was previously notified of its non-compliance on February 22, 2024, due to its share

Full story: https://grafa.com/news/terra-metals--asx-tm1--finds-valuable-minerals-at-dante-project-s-crius-reef-221311 Terra Metals unveiled drill results from its Dante Project, affirming high-grade magmatic sulphides at the Crius Reef. Initial findings from the first three holes of a 10,000m drilling program reveal polymetallic sulphide mineralisation, including copper, platinum group elements, vanadium, and titanium. Intercepts include 5m at 0.56% Cu, 0.53g/t PGE3i, 0.61% V2O5, and 18.5% TiO2 from 80m depth. With assays pending for 5,000m across 30 out of 33

Melbana Energy reached a total depth of 3,645m MD for its Alameda-3 drilling, encountering heightened formation gas. Two core samples await analysis alongside wireline logs to assess further potential. Alameda-3 aims to appraise the Alameda and Marti reservoirs, which hold an estimated 179 million barrels of combined prospective recoverable resources. Melbana's Executive Chairman Andrew Purcell anticipates a successful logging run. Claim Now

Adidas stock price soared more than 7% on Wednesday, reaching a two-year high, after the sportswear manufacturer announced impressive quarterly results and upgraded its 2024 financial forecast. The spike in shares came as the German company revealed it had exceeded analysts' expectations in its recent earnings report on Tuesday. Adidas cited robust sales momentum in its retro "terrace" footwear lines, including popular models like the Samba, Gazelle, and Campus, as key growth drivers. This resurgence in retro styles, along with gains in performance sportswear, contributed significantly to the positive results. Wedbush analysts have noted that these segments are seeing particularly strong demand, which has helped bolster Adidas's market position. Meanwhile, Stifel's Cedric Lecasble emphasiz

Amplia Therapeutics launched a fully underwritten entitlement offer on a 2-for-5 basis to raise approximately $4.3 million. Priced at 5.5 cents per new share, this entails a 35.3% discount to the previous traded price. The funds will fuel crucial development initiatives, such as the Phase 2a ACCENT trial, the production of narmafotinib, and an investigator-initiated trial in ovarian cancer. The proceeds will also support ongoing trials and product development, with interim ACCENT trial results expected in the third quarter. Claim Now

Lincoln Minerals announced a substantial increase in its mineral resource estimate for the Kookaburra Graphite Project on the Eyre Peninsula. Total resources have surged 114% since September 2023, reaching 12.8Mt at 7.6% TGC, equating to about 973,000 tonnes of graphite. The upgrade will support an updated pre-feasibility study for a 60-100ktpa graphite concentrate project. Expansion of the high-grade core and the flat-lying orebody at the Kookaburra Gully extension is expected to enhance the feasibility study's economics. Lincoln Minerals plans additional drilling in 2024 and aims to leverage recent graphite export restrictions in China to meet growing demand. Claim

Arvinas (NASDAQ:ARVN) has announced a significant transaction with Novartis, including a license and asset purchase agreement, bolstering Arvinas’ strategic position in developing treatments for prostate cancer. On April 10, 2024, Arvinas entered into a license agreement granting Novartis an exclusive worldwide license to develop, manufacture, and commercialize ARV-766, Arvinas' advanced PROTAC® androgen receptor degrader, aimed at treating patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis Under the terms of the agreement, Novartis will make an upfront payment of $150 million to Arvinas, with the potential for Arvinas to receive up to an additional $1.01 billion in contingent payments base

Dateline Resources reported new assay results from ongoing diamond drilling at the Colosseum Gold Project in San Bernardino County, California. The latest findings indicated an expansion of the high-grade gold zone, notably 88m at 4.18 g/t Au, including 22.8m at 8.17 g/t Au from the felsite breccia unit. Managing Director Stephen Baghdadi cited accelerated drilling and broad gold mineralisation beyond the previously targeted sedimentary breccia unit. CM24-16 intersected wide zones of gold mineralisation in the felsite breccia unit, hinting at a substantial increase in the project's gold inventory and the potential for future resource estimate revisions.

Negotiations between Salesforce (NYSE:CRM) and Informatica (NYSE:INFA) concerning a potential takeover have reached a standstill due to disagreements over the purchase price, a source close to the matter revealed. The talks, which could have resulted in one of Salesforce's largest acquisitions, have not seen progress as both companies failed to reach a consensus on the valuation.  This development marks a significant pause in what would have been a major expansion for Salesforce, following its historic purchases such as the $27 billion acquisition of Slack Technologies in 2021 and the $15 billion takeover of Tableau Software in 2019. Both Salesforce and Informatica have opted not to comment on the matter. 

Full story: https://grafa.com/news/warriedar-resources--asx-wa8--strikes-gold-at-ricciardo-deposit-in-western-australia-221268 Warriedar Resources announced gold findings at the Ricciardo deposit in Western Australia's Murchison region. Assay results from its latest drilling campaign reveal gold intervals, including 4m at 14.49 g/t gold, 12m at 1.91 g/t gold, and 7m at 1.17 g/t gold. The results expand the known high-grade shoot beneath the Ardmore pit and demonstrate additional mineralisation beyond the current model. The Ricciardo deposit, situated in

The ASX closed down 35 points with the A-REIT sector driving the losses. Of the 50 largest stocks, the most movement has been from Computershare (ASX:CPU) which closed higher by 4.45%, Contact Energy (ASX:CEN) which finished higher by 2.84% and Pilbara Minerals (ASX:PLS) which closed higher by 2.55%. As the top 50 largest companies comprise almost 60% of the total market, any big changes to their share price may influence the overall market. The biggest gainer on the ASX at the close was Krakatoa Resources (ASX:KTA) - which finished 125.00% higher at the close of trade - this is a micro cap company. The biggest loser on the ASX at the close was Tali Digital (ASX:TD1) - which was down 50.00% at the close of trade - this is a micro cap company.